Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorized
  2. c-icon icon-chevron-right
August 18, 2013

Dyax commences dosing in Phase I study of DX-2930

Biopharmaceutical company Dyax has dosed the first subject in a Phase I study of fully human monoclonal antibody inhibitor of plasma kallikrein, DX-2930, leveraging the company’s phage display technology platform.

Biopharmaceutical company Dyax has dosed the first subject in a Phase I study of fully human monoclonal antibody inhibitor of plasma kallikrein, DX-2930, leveraging the company’s phage display technology platform.

The study will assess the safety and tolerability of single administration of DX-2930, developed by the company as a subcutaneous injection for the prevention of hereditary angioedema (HAE) attacks.

Dyax executive vice president and chief medical officer Dr Burt Adelman said that there is a significant requirement for an effective, safe and well tolerated prophylactic agent to treat HAE.

"DX-2930 is a highly potent, long-acting, fully human monoclonal antibody that binds specifically to active plasma kallikrein."

"DX-2930 is a highly potent, long-acting, fully human monoclonal antibody that binds specifically to active plasma kallikrein," Adelman added.

"We look forward to completing this study and moving forward rapidly with this important clinical program."

The single-centre, randomised, double-blind, placebo-controlled study will assess the safety and tolerability of DX-2930 as well as characterise the pharmacokinetics (PK) of single, subcutaneous administrations of the investigational candidate in healthy subjects.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

The study conducted at the clinical trials unit of Vince & Associates Clinical Research will enrol approximately 32 subjects into four ascending dose cohorts (n=8 per cohort) of DX-2930 or placebo.

Dyax president and CEO Gustav Christensen said, "We believe our knowledge of the plasma kallikrein pathway provides us with unique insight and a significant advantage in developing and commercialising this product candidate."

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU